drugset / Trial / NCT04099277
A Study of LY3435151 in Participants With Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The reason for this study is to see if the study drug LY3435151 is safe in participants with advanced solid tumors.
Timeline
- Start
- 2019-10-28
- Primary completion
- 2020-03-05
- Completion
- 2020-03-05
Outcome
Outcome not reported
Stopped (Business): “Study terminated due to strategic business decision by Eli Lilly and Company.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LY3435151 | Unknown | 10 mg | Intravenous |
| Background | Pembrolizumab | Monoclonal antibody | — | Intravenous |